

Supplementary Table 1. Search strategies with appropriated key words and MeSH terms.

Database	Search strategies (search date: August 8, 2023)	Total
LILACS	(tw:("Syndrome oligodontia" OR "syndromes oligodontia" OR "Syndromic oligodontia" OR "oligodontia sindoromica" OR "sindrome oligodontia" OR "sindromes oligodontia" OR "sindrome oligodoncia" OR "oligodoncia sindromica" OR "sindromes oligodoncia" OR "LTBP3" OR "WNT10A" OR "EDARADD" OR "EDA" OR "IKBKG" OR "MSX1" OR "AXIN2")) AND (tw:(anodontismo OR anodontia OR Oligodontia OR "Severe hypodontia" OR anodoncia OR oligodoncia OR "hipodontia severa"))	27
Embase	('anodontia'/exp OR 'anodontia' OR 'oligodontia'/exp OR 'oligodontia' OR 'severe hypodontia') AND ('syndrome oligodontia' OR 'syndromes oligodontia' OR 'syndromic oligodontia' OR 'ltbp3' OR 'wnt10a' OR 'edaradd' OR 'eda'/exp OR 'eda' OR 'ikbkg' OR 'msx1' OR 'axin2'/exp OR 'axin2')	319
PubMed	("Syndrome oligodontia" OR "syndromes oligodontia" OR "Syndromic oligodontia" OR "LTBP3" OR "WNT10A" OR "EDARADD" OR "EDA" OR "IKBKG" OR "MSX1" OR "AXIN2") AND ("anodontia"[MeSH Terms] OR "anodontia" OR "Oligodontia" OR "Severe hypodontia")	1300
Scopus	TITLE-ABS-KEY("Syndrome oligodontia" OR "syndromes oligodontia" OR "Syndromic oligodontia" OR "LTBP3" OR "WNT10A" OR "EDARADD" OR "EDA" OR "IKBKG" OR "MSX1" OR "AXIN2") AND TITLE-ABS-KEY("anodontia" OR "Oligodontia" OR "Severe hypodontia")	412
Livivo	("Syndrome oligodontia" OR "syndromes oligodontia" OR "Syndromic oligodontia" OR "LTBP3" OR "WNT10A" OR "EDARADD" OR "EDA" OR "IKBKG" OR "MSX1" OR "AXIN2") AND ("anodontia" OR "Oligodontia" OR "Severe hypodontia")	151
Web of Science	TS=(Syndrome oligodontia OR syndromes oligodontia OR Syndromic oligodontia OR LTBP3 OR WNT10A OR EDARADD OR EDA OR IKBKG OR MSX1 OR AXIN2) AND TS=(anodontia OR Oligodontia OR Severe hypodontia)	360

Google Scholar	("Syndrome oligodontia" OR "syndromes oligodontia" OR "Syndromic oligodontia" OR "LTBP3" OR "WNT10A" OR "EDARADD" OR "EDA" OR "IKBKG" OR "MSX1" OR "AXIN2") AND ("anodontia"[MeSH Terms] OR "anodontia" OR "Oligodontia" OR "Severe hypodontia")	74
Open Grey	Oligodontia	7

Supplementary Table 2. Risk of bias assessment of the individual articles included (n:84)

Authors / Year	1. Were patient's demographic characteristics clearly described?	2. Was the patient's history clearly described and presented as a timeline?	3. Was the current clinical condition of the patient on presentation clearly described?	4. Were diagnostic tests or assessment methods and the results clearly described?	5. Was the intervention(s) or treatment procedure(s) clearly described?	6. Was the post-intervention clinical condition clearly described?	7. Were adverse events (harms) or unanticipated events identified and described?	8. Does the case report/series provide takeaway lessons?
Abdulla et al., 2019	Unclear	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Abs et al., 1994	Yes	Yes	Yes	no	Not applicable	Not applicable	Not applicable	Yes
Aditya et al., 2011	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Agarwal et al., 2014	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Aminabadi et al., 2010	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Ann Drum et al., 1985	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Ardila and Álvarez-Martínez, 2022	No	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Arora et al., 2016	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Awadh et al., 2016	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Barber et al., 2012	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes

Bekiesinska-Figatowska et al., 2010	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Bergendal, 2001	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Bergendal et al., 2015	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Bildik et al., 2012	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Blankenstein et al., 2001	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Cagetti et al., 2019	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Callanan et al., 2006	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Carvalho et al., 2013	Yes	no	Yes	no	Not applicable	Not applicable	Not applicable	Yes
Chalabreysse et al., 2011	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Cho et al., 2004	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Clauss et al., 2014	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Cogulu and Ertugrul, 2007	Yes	no	Yes	no	Not applicable	Not applicable	Not applicable	Yes
Cogulu and Ertugrul, 2007	Yes	no	Yes	no	Not applicable	Not applicable	Not applicable	Yes
Costa et al., 2022	Yes	No	Yes	No	Not applicable	Not applicable	Not applicable	Yes
Dall'oca et al., 2008	Yes	Unclear	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes

Devadas et al., 2005	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Downing and Welbury, 1992	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Dunbar et al., 2015	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Emral and Akcam, 2009	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Fan et al., 2019	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Ghosh et al., 2019	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Gupta, 2012	Yes	Yes	Yes	no	Not applicable	Not applicable	Not applicable	Yes
Hasan et al., 2019	Yes	Yes	Yes	no	Not applicable	Not applicable	Not applicable	Yes
Hassona et al., 2018	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Hattab et al., 1996	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Hattab et al., 1997	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Hingston et al., 2006	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Jain et al., 2010	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Jain et al., 2012	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Kale et al., 2013	Yes	no	No	Yes	Not applicable	Not applicable	Not applicable	Yes

Kantaputra et al., 2013	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Kaul and Redd, 2008	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Kawamoto, Motohashi and Ohyama, 2004	Yes	Unclear	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Khabour et al., 2010	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Khurana et al., 2010	No	Unclear	Unclear	Yes	Not applicable	Not applicable	Not applicable	Yes
Kinyo et al., 2013	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Kishore et al., 2014	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Kobayashi et al., 2022	No	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Kozma et al., 1999	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Kramer et al., 2005	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Kroigard et al., 2016	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Levy et al., 2020	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Liedén et al., 2016	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Lin et al., 2022	No	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes

<u>Martinho</u> et al., 2019	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Marvin et al., 2011	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Murata et al., 2019	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
O'Dwyer and Jones, 2005	Yes	no	No	no	Not applicable	Not applicable	Not applicable	Yes
Pipa Vallejo et al., 2008	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Reiche et al., 2014	Yes	Unclear	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Retna and Sockalingnam, 2013	Yes	Unclear	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Richieri-Costa et al., 1993	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Rizos et al., 1998	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Rock and McLellan, 2016	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Shen et al., 2011	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Siddiqui et al., 2021	No	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Sikora et al., 2006	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Singh et al., 2017	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes

Subramaniam and Neeraja, 2008	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Suda et al., 2010	Yes	No	No	Yes	Not applicable	Not applicable	Not applicable	Yes
Sultan et al., 2020	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Sun et al., 2019	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Talasila et al., 2017	No	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Tanboga et al., 2001	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Tanboga et al., 1992	Yes	Yes	Yes	Unclear	Not applicable	Not applicable	Not applicable	Yes
Tao et al., 2010	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Tosun et al., 2006	Yes	Yes	Yes	No	Not applicable	Not applicable	Not applicable	Yes
Tuna et al., 2008/ Turkey	Yes	Yes	Yes	no	Not applicable	Not applicable	Not applicable	Yes
Tuna et al., 2009	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Tuna et al., 2012	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Vasudevan and Sinha, 2023	No	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes
Waldron et al., 2010	Yes	Yes	Yes	no	Not applicable	Not applicable	Not applicable	Yes
Yin et al., 2013	Yes	Yes	Yes	Yes	Not applicable	Not applicable	Not applicable	Yes

Zidane and Alloussi, 2022	Yes	Yes	Yes	No	Not applicable	Not applicable	Not applicable	Yes
---------------------------	-----	-----	-----	----	----------------	----------------	----------------	-----

Supplementary Table 3. Biological processes characterized with the list of altered genes in syndromes with oligodontia.

#term ID	Term description	Observed gene count	Background gene count	False discovery rate	Matching proteins in your network
GO:0042476	Odontogenesis	7	126	1.56e-07	WNT10A,LEF1,AXIN2,EDA,MSX1,FGFR2,PITX2
GO:0048732	Gland development	8	419	7.29e-06	WNT10A,CDH1,LEF1,PTCH1,EDA,MSX1,FGFR2,PITX2
GO:0060429	Epithelium development	10	1069	1.65e-05	WNT10A,LEF1,AXIN2,NPHP1,PTCH1,EDA,DSP,MSX1,FGFR2,PITX2
GO:0003007	Heart morphogenesis	6	247	0.00015	AXIN2,PTCH1,DSP,MSX1,FGFR2,PITX2
GO:0009887	Animal organ morphogenesis	9	997	0.00015	WNT10A,LEF1,AXIN2,PTCH1,EDA,DSP,MSX1,FGFR2,PITX2
GO:0003002	Regionalization	6	341	0.00054	LEF1,AXIN2,PTCH1,MSX1,FGFR2,PITX2
GO:0008544	Epidermis development	6	320	0.00054	WNT10A,PTCH1,EDA,DSP,FGFR2,PITX2
GO:0009653	Anatomical structure morphogenesis	11	2229	0.00054	WNT10A,LEF1,AXIN2,NPHP1,PTCH1,EDA,DSP,MSX1,FGFR2,TBCE,PITX2
GO:0030154	Cell differentiation	13	3507	0.00054	WNT10A,CDH1,LEF1,AXIN2,NPHP1,PTCH1,EDARADD,EDA,DSP,MSX1,FGFR2,TBCE,PITX2
GO:0048729	Tissue morphogenesis	7	565	0.00054	WNT10A,LEF1,NPHP1,PTCH1,DSP,MSX1,FGFR2
GO:0048762	Mesenchymal cell differentiation	5	170	0.00054	WNT10A,LEF1,MSX1,FGFR2,PITX2
GO:0060173	Limb development	5	180	0.00054	LEF1,PTCH1,MSX1,FGFR2,PITX2
GO:0030879	Mammary gland development	4	128	0.0037	LEF1,PTCH1,MSX1,FGFR2

GO:0061153	Trachea gland development	2	2	0.0037	LEF1,EDA
GO:0072359	Circulatory system development	7	901	0.0040	LEF1,AXIN2,PTCH1,DSP,MSX1,FGFR2,PITX2
GO:0007423	Sensory organ development	6	577	0.0042	WNT10A,LEF1,NPHP1,MSX1,FGFR2,PITX2
GO:0035108	Limb morphogenesis	4	144	0.0044	LEF1,PTCH1,MSX1,FGFR2
GO:0048731	System development	12	3867	0.0046	WNT10A,CDH1,LEF1,AXIN2,NPHP1,PTCH1,EDA,DSP,MSX1,FGFR2,TBCE,PITX2
GO:0071866	Negative regulation of apoptotic process in bone marrow cell	2	4	0.0061	LEF1,FGFR2
GO:0048513	Animal organ development	11	3246	0.0062	WNT10A,CDH1,LEF1,AXIN2,NPHP1,PTCH1,EDA,DSP,MSX1,FGFR2,PITX2
GO:0021873	Forebrain neuroblast division	2	5	0.0077	LEF1,FGFR2
GO:0007166	Cell surface receptor signaling pathway	9	2040	0.0079	WNT10A,LEF1,AXIN2,PTCH1,EVC2,EDA,MSX1,FGFR2,IKBKG
GO:0030900	Forebrain development	5	391	0.0079	CDH1,LEF1,MSX1,FGFR2,PITX2
GO:0023052	Signaling	13	5057	0.0080	WNT10A,LEF1,AXIN2,NPHP1,PTCH1,EDARADD,EVC2,PCNT,EDA,DSP,MSX1,FGFR2,IKBKG
GO:0048863	Stem cell differentiation	4	183	0.0080	WNT10A,MSX1,FGFR2,PITX2
GO:0008283	Cell population proliferation	6	712	0.0085	LEF1,AXIN2,PTCH1,MSX1,FGFR2,PITX2
GO:0071864	Positive regulation of cell proliferation in bone marrow	2	6	0.0085	LEF1,FGFR2

GO:0007154	Cell communication	13	5165	0.0089	WNT10A,LEF1,AXIN2,NPHP1,PTCH1,EDARADD,EVC2,PCNT,EDA,DSP,MSX1,FGFR2,IKBKG
GO:0061180	Mammary gland epithelium development	3	61	0.0089	PTCH1,MSX1,FGFR2
GO:0048699	Generation of neurons	7	1131	0.0096	WNT10A,CDH1,LEF1,PTCH1,FGFR2,TBCE,PITX2
GO:0010604	Positive regulation of macromolecule metabolic process	11	3533	0.0099	WNT10A,CDH1,SrcAP,LEF1,AXIN2,PTCH1,EDA,MSX1,FGFR2,IKBKG,PITX2
GO:0002009	Morphogenesis of an epithelium	5	457	0.0117	WNT10A,LEF1,NPHP1,PTCH1,FGFR2
GO:0007420	Brain development	6	775	0.0117	CDH1,LEF1,PTCH1,MSX1,FGFR2,PITX2
GO:0048568	Embryonic organ development	5	454	0.0117	LEF1,PTCH1,MSX1,FGFR2,PITX2
GO:0060348	Bone development	4	216	0.0117	AXIN2,MSX1,FGFR2,PITX2
GO:0045893	Positive regulation of transcription, DNA-templated	8	1710	0.0129	CDH1,SrcAP,LEF1,PTCH1,MSX1,FGFR2,IKBKG,PITX2
GO:0001837	Epithelial to mesenchymal transition	3	79	0.0141	LEF1,MSX1,FGFR2
GO:0001942	Hair follicle development	3	80	0.0141	WNT10A,EDA,FGFR2
GO:0061053	Somite development	3	82	0.0149	LEF1,AXIN2,PTCH1
GO:0042475	Odontogenesis of dentin-containing tooth	3	83	0.0151	LEF1,EDA,MSX1

GO:0050896	Response to stimulus	15	7835	0.0152	WNT10A,CDH1,LEF1,AXIN2,NPHP1,PTCH1,EDARADD,EVC2,PCNT,EDA,DSP,MSX1,FGFR2,TBCE,IKBKG
GO:0007165	Signal transduction	12	4714	0.0162	WNT10A,LEF1,AXIN2,NPHP1,PTCH1,EDARADD,EVC2,PCNT,EDA,MSX1,FGFR2,IKBKG
GO:0043588	Skin development	4	266	0.0174	WNT10A,EDA,DSP,FGFR2
GO:0016055	Wnt signaling pathway	4	284	0.0206	WNT10A,LEF1,AXIN2,EDA
GO:0048646	Anatomical structure formation involved in morphogenesis	6	938	0.0206	LEF1,AXIN2,PTCH1,EDA,MSX1,FGFR2
GO:0060070	Canonical Wnt signaling pathway	3	100	0.0206	WNT10A,LEF1,EDA
GO:0060349	Bone morphogenesis	3	100	0.0206	AXIN2,MSX1,FGFR2
GO:0022612	Gland morphogenesis	3	104	0.0212	PTCH1,EDA,FGFR2
GO:0071310	Cellular response to organic substance	8	2019	0.0267	WNT10A,CDH1,LEF1,AXIN2,PTCH1,EDA,MSX1,FGFR2
GO:0010092	Specification of animal organ identity	2	18	0.0272	AXIN2,FGFR2
GO:0042481	Regulation of odontogenesis	2	18	0.0272	WNT10A,MSX1
GO:0030111	Regulation of Wnt signaling pathway	4	326	0.0289	LEF1,AXIN2,EDA,FGFR2
GO:0030326	Embryonic limb morphogenesis	3	120	0.0289	LEF1,PTCH1,MSX1
GO:0043586	Tongue development	2	20	0.0289	WNT10A,LEF1

GO:0060537	Muscle tissue development	4	323	0.0289	PTCH1,DSP,MSX1,FGFR2
GO:0009790	Embryo development	6	1049	0.0300	LEF1,AXIN2,PTCH1,MSX1,FGFR2,PITX2
GO:0045667	Regulation of osteoblast differentiation	3	125	0.0300	AXIN2,PTCH1,FGFR2
GO:0030182	Neuron differentiation	6	1062	0.0314	WNT10A,CDH1,PTCH1,FGFR2,TBCE,PITX2
GO:0043009	Chordate embryonic development	5	654	0.0314	LEF1,AXIN2,PTCH1,MSX1,FGFR2
GO:0048518	Positive regulation of biological process	13	6207	0.0314	WNT10A,CDH1,SRCAP,LEF1,AXIN2,NPHP1,PTCH1,PCNT,EDA,MSX1,FGFR2,IKBKG,PITX2
GO:0010839	Negative regulation of keratinocyte proliferation	2	22	0.0319	PTCH1,FGFR2
GO:0060713	Labyrinthine layer morphogenesis	2	22	0.0319	LEF1,FGFR2
GO:0048754	Branching morphogenesis of an epithelial tube	3	134	0.0340	LEF1,PTCH1,FGFR2
GO:0007399	Nervous system development	8	2188	0.0360	WNT10A,CDH1,LEF1,PTCH1,MSX1,FGFR2,TBCE,PITX2
GO:0071495	Cellular response to endogenous stimulus	6	1103	0.0360	WNT10A,CDH1,LEF1,AXIN2,MSX1,FGFR2
GO:0030177	Positive regulation of Wnt signaling pathway	3	141	0.0374	LEF1,EDA,FGFR2
GO:0051716	Cellular response to stimulus	13	6357	0.0374	WNT10A,CDH1,LEF1,AXIN2,NPHP1,PTCH1,EDARADD,EVC2,PCNT,EDA,MSX1,FGFR2,IKBKG

GO:0000902	Cell morphogenesis	5	708	0.0401	LEF1,PTCH1,MSX1,FGFR2,TBCE
GO:0007435	Salivary gland morphogenesis	2	27	0.0423	EDA,FGFR2
GO:0010463	Mesenchymal cell proliferation	2	27	0.0423	MSX1,FGFR2
GO:0035148	Tube formation	3	150	0.0426	PTCH1,EDA,FGFR2
GO:0030030	Cell projection organization	6	1158	0.0431	CDH1,NPHP1,PTCH1,PCNT,FGFR2,TBCE
GO:0033688	Regulation of osteoblast proliferation	2	28	0.0436	AXIN2,FGFR2
GO:0001701	In utero embryonic development	4	393	0.0450	LEF1,PTCH1,MSX1,FGFR2
GO:0051252	Regulation of RNA metabolic process	10	3759	0.0471	CDH1,SrcAP,LEF1,AXIN2,PTCH1,EDA,MSX1,FGFR2,IKBKG,PITX2
GO:0048468	Cell development	7	1719	0.0478	CDH1,LEF1,AXIN2,PTCH1,FGFR2,TBCE,PITX2
GO:0031069	Hair follicle morphogenesis	2	31	0.0496	WNT10A,FGFR2
GO:0048522	Positive regulation of cellular process	12	5584	0.0496	CDH1,SrcAP,LEF1,AXIN2,NPHP1,PTCH1,PCNT,EDA,MSX1,FGFR2,IKBKG,PITX2
GO:0060325	Face morphogenesis	2	31	0.0496	LEF1,MSX1
GO:0060603	Mammary gland duct morphogenesis	2	31	0.0496	PTCH1,FGFR2

Supplementary Table 4. Activated pathways characterized with syndromes with oligodontia.

#term ID	Term description	Observed gene count	Background gene count	False discovery rate	Matching proteins in your network
hsa05200	Pathways in cancer	7	515	4.55e-05	WNT10A,CDH1,LEF1,AXIN2,PTCH1,FGFR2,IKBKG
hsa05217	Basal cell carcinoma	4	63	4.55e-05	WNT10A,LEF1,AXIN2,PTCH1
hsa05226	Gastric cancer	5	146	4.55e-05	WNT10A,CDH1,LEF1,AXIN2,FGFR2
hsa04390	Hippo signaling pathway	4	154	0.00073	WNT10A,CDH1,LEF1,AXIN2
hsa05213	Endometrial cancer	3	58	0.0012	CDH1,LEF1,AXIN2
hsa04064	NF-kappa B signaling pathway	3	101	0.0046	EDARADD,EDA,IKBKG
hsa05215	Prostate cancer	3	97	0.0046	LEF1,FGFR2,IKBKG
hsa04550	Signaling pathways regulating pluripotency of stem cells	3	141	0.0101	WNT10A,AXIN2,FGFR2
hsa05224	Breast cancer	3	146	0.0101	WNT10A,LEF1,AXIN2
hsa04310	Wnt signaling pathway	3	154	0.0102	WNT10A,LEF1,AXIN2
hsa04934	Cushing syndrome	3	153	0.0102	WNT10A,LEF1,AXIN2
hsa05225	Hepatocellular carcinoma	3	161	0.0102	WNT10A,LEF1,AXIN2
hsa05216	Thyroid cancer	2	37	0.0132	CDH1,LEF1

hsa04340	Hedgehog signaling pathway	2	46	0.0185	PTCH1,EVC2
hsa04520	Adherens junction	2	69	0.0355	CDH1,LEF1
hsa05221	Acute myeloid leukemia	2	67	0.0355	LEF1,IKBKG
hsa05412	Arrhythmogenic right ventricular cardiomyopathy	2	77	0.0410	LEF1,DSP
hsa05210	Colorectal cancer	2	82	0.0437	LEF1,AXIN2
hsa05165	Human papillomavirus infection	3	324	0.0457	WNT10A,AXIN2,IKBKG
